2021
Automated Insulin Delivery
Weinzimer S, Carria L, Van Name M. Automated Insulin Delivery. Contemporary Endocrinology 2021, 75-85. DOI: 10.1007/978-3-030-64133-7_8.ChaptersDiabetes self-management tasksInsulin deliveryHemoglobin A1c levelsT1D Exchange RegistrySelf-management tasksGlycemic targetsA1c levelsDiabetes careContinuous glucose monitoring devicesDiabetes therapyInsulin pumpGlucose monitoring devicesDiabetes technologyRecent dataMost youthMore burdenDiabetes devicesBurdenDeliveryT1DRegistryTherapy
2020
1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System
COMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System. Diabetes 2020, 69 DOI: 10.2337/db20-1298-p.Peer-Reviewed Original ResearchMeals/snacksDiabetes careHybrid closed-loop insulin delivery systemParents of youthMental burdenClosed-loop insulin delivery systemBoehringer Ingelheim PharmaceuticalsSanofi UST1D durationDiabetes CenterCarbohydrate intakeSpouse/partnerInsulin delivery systemsDietary restrictionJanssen PharmaceuticalsArtificial pancreas systemsYoung adultsInsulin deliverySpeakers bureauCareIntakeCGM usersAge 10National InstituteEli Lilly8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D
HUGHES A, BISPHAM J, FULLER L, WOLF W, FITCH S, WEINZIMER S. 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D. Diabetes 2020, 69 DOI: 10.2337/db20-8-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaPerspectives of peopleUse of glucagonAdministration of glucagonMinimal side effectsMode of administrationHypoglycemic emergenciesGlycemic targetsInsulin therapyDiabetes careSpouse/partnerEmergency treatmentEffective treatmentHypoglycemiaSide effectsT1DGlucagonEmotional impactEmergency useCaregiversT1D.Administration typeFeelings of distressAdministrationParticipants998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents
ROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents. Diabetes 2020, 69 DOI: 10.2337/db20-998-p.Peer-Reviewed Original ResearchDiabetes careT1D durationInsulin pumpType 1 diabetesBoehringer Ingelheim PharmaceuticalsSanofi USDiabetes CenterDifferent treatment situationsSpouse/partnerInsulin delivery systemsCare burdenGlucose levelsJanssen PharmaceuticalsT1DArtificial pancreas systemsDiabetesEmotional burdenParents of youthYoung adultsSpeakers bureauCareAge 10Emotional distressNational InstituteUnderwent content analysis
2019
1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes
FOLAND-ROSS L, BUCKINGHAM B, MAURAS N, ARBELAEZ A, WHITE N, AYE T, WILSON D, TAMBORLANE W, WEINZIMER S, TSALIKIAN E, TANSEY M, CATO A, HERSHEY T, FOX L, TONG G, ENGLERT K, MAZAIKA P, REISS A. 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1382-p.Peer-Reviewed Original ResearchDefault mode networkExecutive control regionsDiabetes careMedtronic MiniMedSpouse/partnerGreater activationEunice Kennedy Shriver National InstituteLess suppressionEffects of dysglycemiaAdvisory PanelEli LillySimilar task performanceExecutive control areasParent-report measuresTakeda Pharmaceutical Company LimitedNondiabetic childrenT1D groupHbA1c levelsNondiabetic controlsSlower processing speedT1D onsetHigher HbA1cChild healthResearch supportMulti-site study1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D)
COMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-1361-p.Peer-Reviewed Original ResearchDiabetes careGlycemic benefits816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)
COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-816-p.Peer-Reviewed Original ResearchDiabetes careBurden of T1DSelf-care burdenDiabetes technologyType 1 diabetesEli LillyArtificial pancreasUnderwent thematic analysisT1D durationNovo Nordisk A/SCarbohydrate countingSpouse/partnerCare burdenSemi-structured qualitative interviewsT1D careJanssen PharmaceuticalsMedtronic MiniMedPatients' hopeAP uptakeHeart rate monitorT1DDiabetesYoung adultsSpeakers bureauCare817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey
COMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey. Diabetes 2019, 68 DOI: 10.2337/db19-817-p.Peer-Reviewed Original ResearchDiabetes careYoung personLess diabetes distressType 1 diabetesEli LillyInternal consistencyAdvanced diabetes technologiesMale sexDiabetes distressNovo Nordisk A/SSpouse/partnerGood internal consistencyT1D careDiabetesJanssen PharmaceuticalsMedtronic MiniMedMultidisciplinary teamTreatment surveySignificant associationPsychosocial outcomesYouth ages 8T1DCeiling effectsTotal scoreIllness identity209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet)
ARBELAEZ A, O’DONOGHUE S, MAURAS N, BUCKINGHAM B, WHITE N, WEINZIMER S, AYE T, TSALIKIAN E, WILSON D, TAMBORLANE W, TANSEY M, CATO A, HERSHEY T, FOX L, ENGLERT K, REISS A. 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet). Diabetes 2019, 68 DOI: 10.2337/db19-209-or.Peer-Reviewed Original ResearchDiabetes careNondiabetic controlsVoxel-based morphometryMedtronic MiniMedWhite matterSubcortical GMSpouse/partnerEarly-onset type 1 diabetesEunice Kennedy Shriver National InstituteAge-matched nondiabetic controlsEarly-onset T1DTime of diagnosisWorse glycemic controlType 1 diabetesEffects of T1DBasal ganglia regionsAdvisory PanelRapid brain maturationWhite matter areasEli LillyGray matter volumeGray matter regionsTakeda Pharmaceutical Company LimitedGlycemic exposureT1D children
2018
Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management
Adams RN, Tanenbaum ML, Hanes SJ, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology & Therapeutics 2018, 20: 648-653. PMID: 30239219, DOI: 10.1089/dia.2018.0174.Peer-Reviewed Original ResearchConceptsManagement distressHuman factorsTechnology attitudesGlycemic outcomesType 1 diabetes outcomesHybrid closed-loop systemPsychosocial factorsMultisite clinical trialTrial periodDistressTrial exposureFear of hypoglycemiaDiabetes careOutpatient settingDiabetes outcomesClinical trialsType 1Insulin deliveryTrialsAttitudesOutcomesT-testRegression analysisFurther investigationAdolescentsExceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study
PINSKER J, LI Z, BUCKINGHAM B, FORLENZA G, CENGIZ E, CHURCH M, EKHLASPOUR L, PAUL WADWA R, WEINZIMER S, ANDRE C, MARCAL T, JOST E, CARRIA L, WOODALL W, DOKKEN B, SWANSON V, LUM J, KOLLMAN C, BECK R. Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study. Diabetes 2018, 67 DOI: 10.2337/db18-86-lb.Peer-Reviewed Original Research
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatment